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Background: The aim was to identify potential risk factors for lethal outcome in patients with delirium tremens
(DT) treated in the psychiatric setting.
Methods: In a nested case-control study, a total of 190 medical records of patients with DT hospitalized at the
Psychiatric Clinic in Serbia between 2002 and 2011 were reviewed and analyzed. The characteristics of patients
who died (cases) were compared with those who survived (controls). For each case, two controls (matched for age,
gender, and year of hospitalization) were randomly chosen.
Results: Significant differences between cases and controls were found for serum potassium levels (p < 0.001), the
number of hospitalizations (p < 0.001), and duration of hospitalization (p < 0.001). A significant association with
lethal outcome was found for serum potassium levels even in the normal range (adjusted odds ratio 40.52;
95% CI 1.20, >1,000.00; p = 0.004).
Conclusions: Even though the number and duration of psychiatric hospitalizations were identified as factors
determining survival after admission for DT, only serum potassium levels were found to be significant. Patients
with an increase in potassium (or absence of hypokalemia) may require more intensive treatment. Monitoring
of serum levels of potassium is important not only as an indicator for replacement but also as an indicator of
maladaptation.
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(duration of hospitalization)Background
Delirium tremens (DT) is the severest form of alcohol
withdrawal and is recorded in approximately 5% to 24%
of patients [1-5]. Over the last few decades, the mortality
rate for patients with DT has fallen from 35% to 2%, and
this has been largely attributed to improved diagnostic
and pharmacological measures [2,6-11]. Several studies
have identified risk factors for the occurrence of DT
[5,12-18], but there has been little research into the risk
factors for mortality among patients with DT [3,6,10,18,19].
The factors that predict a fatal outcome in patients with
DT remain unclear, and DT is still categorized as an* Correspondence: nece84@hotmail.com
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distribution, and reproduction in any mediumemergency [2,3,5,20]. The early recognition of risk factors
for DT mortality in patients will facilitate the introduction
of preventative measures to decrease the likelihood of a
fatal outcome [3,21]. The danger of a fatal outcome in the
psychiatric setting, where DT patients are first seen or
treated, additionally highlights the importance of early rec-
ognition and treatment of DT.
The aim of the study was to identify important risk
factors for fatal outcome in patients with DT who
presented for admission at the Psychiatric Clinic of the
Clinical Center ‘Kragujevac’ in Serbia.Methods
Study design
The study design is a nested case-control study.Central Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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Figure 1 Number of patients per year in groups (cases, controls,
all survivors, and all patients with DT).
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The study was conducted using data obtained for all
patients with DT (n = 190) who were hospitalized at the
Psychiatric Clinic of the Clinical Center ‘Kragujevac’ in
Serbia, during the 10-year period (2002–2011). Patients
were included in the study if they were 18 years of age
and above and if they fulfilled the International Classi-
fication of Diseases (ICD-10) criteria for DT [22,23].
Patients with incomplete data sets were excluded. Cases
(n = 14) were defined as patients who had died from DT.
Two controls (n = 28) were identified for each case;
matched for gender, age, and calendar year in which they
were treated; and randomly selected from the patients
with DT who had been successfully treated and dis-
charged alive. All patients were treated according to the
standardized therapeutic protocol at the clinic. Ethical
approval was obtained from the ethical committee of
Clinical Center ‘Kragujevac’ and the principles of Good
Clinical Practice were strictly followed.
Study protocol
For all patients, we collected demographic data (age,
gender, marital and educational status) and variables
relating to alcohol consumption (heredity factors, dur-
ation of alcohol consumption). Serum potassium levels,
aspartate aminotransferase/alanine aminotransferase
levels (AST/ALT), and level of creatine phosphokinase
(CPK) in serum were measured in each patient on the
day of admission. Data on further potential risk factors
for a fatal outcome were also recorded, namely, exist-
ence of liver lesions (clinical diagnosis by gastroenterolo-
gist, without ultrasound confirmation), epileptic seizure
during the 24 to 48 h following admission (without
previous epilepsy), transfer to another clinical department,
and number and duration of previous hospitalizations for
alcohol-related health problems at this clinic.
Statistical analysis
Statistical analysis was carried out using the statistical
software IBM SPSS version 19. Continuous variables
were summarized as means (M) and standard deviations
(SDs). Categorical variables were presented as the fre-
quency of exposure (%) for each risk factor. For categor-
ical variables, the frequency of exposure in cases was
compared to that of controls using chi-square test or
Fisher's exact test (χ2) (where the frequency in a category
was small). Continuous variables were compared using
Student's t test (t) for independent samples and the
Mann-Whitney test (U). Normality of the data was
assessed using the Kolmogorov-Smirnov test. The associ-
ation between potential risk factors and lethal outcome was
evaluated using binary logistic regression, expressing the
strength of association by crude and adjusted odds ratio
(OR) with 95% confidence intervals (CI). All significancetests were performed using a two-sided significance level
of 5% (p < 0.05). The data were analyzed unmatched due
to the small sample size.
Results
In total, 190 (189 males, 1 female) patients satisfying the
study criteria were identified during the study period. Of
these, 14 (7.37%) patients died (cases). The mean age of
all studied patients was 51.39 ± 9.82 years. Only two
variables were independently associated with a fatal
outcome. They were age and potassium levels in serum.
Patients in the deceased group were significantly older
(p = 0.037) and showed significantly higher serum potas-
sium levels (p < 0.001); however, the levels were still
within the normal range (Figure 1 and Table 1).
Cases and controls
Baseline characteristics for cases and controls are
presented in Table 1. Serum potassium levels were
significantly (p < 0.001) higher in cases even in the nor-
mal range (4.50 ± 0.71 mmol/l) compared to controls
(3.74 ± 0.59 mmol/l). Cases also had a significantly
greater number of hospitalizations (p < 0.001) and longer
durations of hospitalization (p < 0.001). The multivariate
analysis, using binary logistic regression analysis with
adjustment for the risk factors, is summarized in
Table 2. There was an independent significant associ-
ation between lethal outcome and serum potassium level
(ORadjusted 40.52; 95% CI 1.20, >1,000.00; p = 0.004).
Discussion
The psychiatric setting is not usually the location of
choice for treating patients with DT. However, histo-
rically, DT has been considered as a consequence of
alcoholism, and so all patients with DT are still primarily
treated at the Psychiatric Clinic of the Clinical Center
‘Kragujevac’. In spite of that, mortality during the 10
years of our study was 7.37% which is similar to that
recorded in other studies [2,3,6,9-11,24]. The lethal
outcome was not registered during the last 3 years
Table 1 Baseline characteristics of participants
Cases Controls Case/controls
statistics
All survivors All patients
(cases + all survivors)
Sex
Male 14 28 175 (99.4%) 189 (99.5%)
Female - - 1 (0.6%) 1 (0.5%)
Age M ± SD 56.64 ± 11.34 56.39 ± 9.51 t(40) = −0.075; p = 0.940 50.97 ± 9.60 51.39 ± 9.82
Death
No - 28 176 176 (92.6%)
Yes 14 - - 14 (7.4%)
Heredity
No 11 (78.6%) 19 (67.9%) χ2(1) = 0.131; p = 0.717 106 (60.2%) 116 (61.1%)
Yes 3 (21.4%) 9 (32.1%) 48 (27.3%) 51 (26.8%)
Missing - - 23 (12.5%) 23 (12.1%)
Hospitalization
> 1 11 (78.6%) 6 (21.4%) χ2(1) = 12.649; p = 0.001* 108 (61.4%) 119 (62.6%)
First 3 (21.4%) 22 (78.6%) 60 (34.1%) 63 (33.2%)
Missing - - 8 (4.5%) 8 (4.2%)
Duration of treatment in days M ± SD 4.29 ± 3.77 17.89 ± 11.90 U = 21.000; p = 0.000* 16.34 ± 8.39 15.43 ± 8.73
Marital status
Not married 8 (57.1%) 20 (71.4%) χ2(1) = 0.857; p = 0.355 58 (33.0%) 66 (34.7%)
Married/widower 6 (42.9%) 8 (28.6%) 104 (59.1%) 110 (57.9%)
Missing - - 14 (8.0%) 14 (7.4%)
Professional qualifications
High 6 (42.9%) 16 (57.1%) χ2(1) = 0.764; p = 0.382 53 (30.1%) 59 (31.1%)
Low 8 (57.1%) 12 (42.9%) 107 (60.8%) 115 (60.5%)
Missing - - 16 (9.1%) 16 (8.4%)
Duration of alcohol consumption
in years M ± SD
19.64 ± 10.02 20.39 ± 12.20 U = 193.500; p = 0.946 17.41 ± 8.51 17.59 ± 8.63
K+ in serum M ± SD 4.50 ± 0.71 3.74 ± 0.59 t(40) = −3.661; p = 0.001* 3.87 ± 1.62 3.92 ± 1.58
AST/ALT ratio M ± SD 2.04 ± 1.43 1.80 ± 0.77 t(40) = −0.600; p = 0.557 2.05 ± 2.06 2.05 ± 2.01
CPK in serum M ± SD 2,910.79 ± 7,323.98 1,421.39 ± 1,841.46 U = 180.000; p = 0.669 1,413.82 ± 2,693.66 1,555.43 ± 3,391.42
Epileptic status
No 11 (78.6%) 22 (78.6%) χ2(1) = 0.000; p = 1.000 117 (66.5%) 128 (67.4%)
Yes 3 (21.4%) 6 (21.4%) 56 (31.8%) 59 (31.1%)
Missing - - 3 (1.7%) 3 (1.6%)
Liver damage
No 10 (71.4%) 18 (64.3%) χ2(1) = 0.214; p = 0.643 129 (73.3%) 139 (73.2%)
Yes 4 (28.6%) 10 (35.7%) 43 (24.4%) 47 (24.7%)
Missing - - 4 (2.3%) 4 (2.1%)
Transfer to another department
No 13 (92.9%) 24 (85.7%) χ2(1) = 0.454; p = 0.500 145 (82.4%) 158 (83.2%)
Yes 1 (7.1%) 4 (14.3%) 27 (15.3%) 28 (14.7%)
Missing - - 4 (2.3%) 4 (2.1%)
*p < 0.05 (significant difference); K+, potassium in serum; AST/ALT, aspartate aminotransferase/alanine aminotransferase; CPK, creatine phosphokinase; M, mean;
SD, standard deviation.
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Table 2 Crude and adjusted odds ratios of the risk factors for mortality in DT
Variables Adjusted OR (95% CI) p Crude OR (95% CI) p
Age 1.49 (0.88, 2.54) 0.141 1.00 (0.94, 1.07) 0.939
Hospitalization 0.014 (0.00, 1.98) 0.091 1.35 (0.63, 2.82) 0.001
Marital status 3.40 (0.12, 99.96) 0.479 1.88 (0.49, 7.15) 0.357
Education >100.00 (0.04, >1,000.00) 0.193 1.78 (0.49, 6.50) 0.384
Duration of consumption 0.63 (0.35, 1.12) 0.116 0.99 (0.94, 1.05) 0.839
Potassium in serum 40.52 (1.20, >1,000.00)a 0.039* 5.78 (1.75, 19.12)a 0.004*
AST/ALT ratio 17.25 (0.30, >100.00) 0.168 1.26 (0.68, 2.33) 0.466
CPK in serum 1.00 (1.00, 1.00) 0.570 1.00 (1.00, 1.00) 0.365
Epileptic status 88.63 (0.27, >1,000.00) 0.128 1.00 (0.21, 4.78) 1.000
Liver lesions 0.00 (0.00, 20.07) 0.172 0.72 (0.18, 2.90) 0.644
Transfer to another department 0.01 (0.00, >1,000.00) 0.397 0.46 (0.05, 4.57) 0.509
According to year of admission 7.66 (0.52, 113.24) 0.139 1.28 (0.91, 1.80) 0.152
*p < 0.05 (significant difference); aClinical significance (OR > 3); AST/ALT, aspartate aminotransferase/alanine aminotransferase; CPK, creatine phosphokinase;
OR, odds ratio; CI, confidence interval.
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atric Clinic.
Although the risk factors for DT are well recognized,
their association with mortality is less well understood.
Patients' age, comorbidities, duration of alcohol consump-
tion, duration of treatment, serum potassium level, and
history of epileptic seizures were identified as the most
significant predictors of mortality in DT in previous
research [2,6,17,19,21,23].
There are a number of studies which point to a drop
in the serum potassium level during weaning from alco-
hol, especially when this is complicated further by DT
[17,21,25-30]. Hypokalemia is actually a part of the com-
plex adaptive mechanism, activated by the patient's body
in order to overcome disturbances caused by a sudden
lack of ethanol in the blood. The sympathetic system is
activated, and consequently, blood levels of aldosterone
and atrial natriuretic peptide (ANP) rise to very high
levels [31,32]. The natriuretic effect of ANP is counter-
balanced by the retention of sodium which is achieved
by the aldosterone effects on renal tubules. The effect is
maintenance of blood pressure and prevention of intra-
cellular edema. However, the reabsorption of sodium by
the renal tubules is accompanied by a loss of potassium
into urine, as each sodium ion is exchanged for one
potassium ion. Hence, high serum potassium levels in a
patient with DT could indicate inappropriate adaptation
to alcohol withdrawal and predict a fatal outcome in that
patient [33].
Therefore, our observation that increased serum
levels of potassium are associated with fatal outcome
in DT patients is not surprising. Monitoring of serum
levels of potassium is important not only as an
indicator for replacement but also as an indicator of
maladaptation. Patients with an increase in potassium(or absence of hypokalemia) may require more inten-
sive treatment.
It is important to note that the average length of treat-
ment for all cases was short (4.29 ± 3.77 days), and more
than 60% of these patients died within the first 4 days
following admission (four patients died on the day of ad-
mission, two on the second day, one on the third day,
and two died on the fourth day). The length of treat-
ment has also been found to be associated with mortality
in previous studies [18,21]. It is clear that the adaptive
mechanisms of these patients had been surpassed and
that they required more intensive monitoring and
treatment. In particular, the absence of adaptive hypokal-
emia was an early sign of maladaptation and should have
indicated that these patients required more intensive
treatment.
Conclusions
The factors determining survival after admission for
delirium tremens in the psychiatric setting depend on
serum potassium levels, the number of hospitalizations,
and duration of hospitalization. A significant association
with lethal outcome was found only for serum potassium
levels even in the normal range. Monitoring of serum
levels of potassium is important not only as an indicator
for replacement but also as an indicator of maladaptation.
Patients with an increase in potassium (or absence of
hypokalemia) may require more intensive treatment. The
future researches are necessary in a larger sample of
patients for better understanding of risk factors for lethal
outcome in patients with delirium tremens.
Limitations
The major limitation of the study relates to the small sam-
ple size due to low mortality over the study period. Also,
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chlorides, bicarbonates, blood urea nitrogen, ketones,
magnesium, and pH, were not considered as this was a
retrospective study and the necessary data had not been
recorded. As a result, the findings of the study should be
interpreted with caution and regarded as hypothesis-
generating, in terms of predictive value of the absence of
hypokalemia for fatal outcome in patients with DT.
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